-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on WAVE Life Sciences, Raises Price Target to $32

Benzinga·12/16/2025 15:03:46
语音播报
Oppenheimer analyst Cheng Li maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises the price target from $24 to $32.